Download PDF
Thromb Haemost 2002; 88(04): 598-604
DOI: 10.1055/s-0037-1613262
Review Article
Schattauer GmbH

Clinical Use of a Rapid Collagen Binding Assay for von Willebrand Factor Cleaving Protease in Patients with Thrombotic Thrombocytopenic Purpura

Margaret E. Rick
1   Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
,
Stephan Moll
2   Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
,
Mark A. Taylor
2   Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
,
Dennis M. Krizek
1   Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
,
Gilbert C. White II
2   Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
,
David L. Aronson
1   Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
› Author Affiliations
Further Information

Publication History

Received 26 November 2001

Accepted after resubmission 19 June 2002

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

A simple collagen binding assay (CBA) for measuring activity of the von Willebrand factor cleaving protease in clinical samples is described, and results of fifty masked plasmapheresis samples from patients with TTP/HUS and other diseases are presented.

There was 97.5% concordance between the CBA and a multimer gel assay. The CBA identified low protease activity in 78% of patients who had a clinical syndrome consistent with TTP/HUS and in 2 of 10 sick controls, giving it a positive predictive value of 0.94. The heterogeneity regarding the presence or absence of vWF protease activity in patients with TTP/HUS was confirmed by finding a low negative predictive value of 0.50 with the CBA. The CBA detected inhibitors of the protease in 26 of 29 patients (90%) with TTP/HUS and low protease activity levels. The CBA is a useful clinical assay for examining von Willebrand factor protease activity and detecting inhibitors against the protease.

Keywords

vWF protease assay - TTP - HUS - collagen - multimers
 

  • References

  • 1 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-59.
    CrossrefPubMedGoogle Scholar
  • 2 Chow TW, Turner NA, Chintagumpala M, McPherson PD, Nolasco LH, Rice L, Hellums JD, Moake JL. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998; 57: 293-302.
    CrossrefPubMedGoogle Scholar
  • 3 Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
    CrossrefPubMedGoogle Scholar
  • 4 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
    CrossrefPubMedGoogle Scholar
  • 5 Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 1654-61.
    CrossrefPubMedGoogle Scholar
  • 6 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
    CrossrefPubMedGoogle Scholar
  • 7 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 1059-61.
    PubMedGoogle Scholar
  • 8 Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49: 653-9.
    CrossrefPubMedGoogle Scholar
  • 9 Hunt BJ, Lämmle B, Nevard CH, Haycock GB, Furlan M. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85: 975-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72.
    CrossrefPubMedGoogle Scholar
  • 11 Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
    CrossrefPubMedGoogle Scholar
  • 12 Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Aronson DL, Krizek DM, Rick ME. A rapid assay for the vWF protease. Thromb Haemost 2001; 85: 184-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
    CrossrefPubMedGoogle Scholar
  • 15 Rock G, Shumak K, Kelton J, Blanchette VS, Buskard N, Nair R, Spasoff R. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange Canadian Apheresis Study Group. Transfusion 1992; 32: 710-4.
    PubMedGoogle Scholar
  • 16 Krizek DM, Rick ME. A rapid method to visualize von willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thromb Res 2000; 97: 457-62.
    CrossrefPubMedGoogle Scholar
  • 17 Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-6.
    CrossrefPubMedGoogle Scholar
  • 18 Kaiser C, Distler W. Thrombotic thrombocytopenic purpura and HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome: differential diagnostic problems. Am J Obstet Gynecol 1996; 175: 506-7.
    CrossrefPubMedGoogle Scholar
  • 19 Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-9.
    PubMedGoogle Scholar
  • 20 van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, Fijnheer R. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-802.
    PubMedGoogle Scholar
  • 21 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
    CrossrefPubMedGoogle Scholar